Cases Methotrexate pneumonitis in a patient with gestational trophoblastic neoplasia
Main Article Content
Abstract
Methotrexate, an immunomodulatory agent used for a wide variety of indications, can cause pulmonary toxicity in the form of pneumonitis, organising pneumonia, pulmonary fibrosis, pleural effusion, pulmonary infections or lymphoproliferative disease. We report a case of methotrexate pneumonitis in a patient with gestational trophoblastic neoplasia. The diagnosis of methotrexate pneumonitis is challenging, as the signs and symptoms can be caused by intercurrent infection, concomitant medications or an underlying disease condition. A high index of suspicion is required for diagnosis. Management consists of drug discontinuation and steroids in patients with respiratory failure.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
How to Cite
References
Jakubovic BD, Donovan A, Webster PM, Shear NH. Methotrexate-induced pulmonary toxicity. Can Respir J 2013;20(3):153-155. https://doi. org/10.1155/2013/527912
Chhabra P, Law AD, Suri V, Malhotra P, Varma S. Methotrexate induced lung injury in a patient with primary CNS lymphoma: A case report. Mediterr J Hematol Infect Dis 2012;4(1):e2012020. https://doi. org/10.4084/MJHID.2012.020
Salehi M, Miller R, Khaing M. Methotrexate-induced hypersensitivity pneumonitis appearing after 30 years of use: A case report. J Med Case Rep 2017;11(1):174. https://doi.org/10.1186/s13256-017-1333-0
Imokawa S, Colby TV, Leslie KO, Helmers RA. Methotrexate pneumonitis: Review of the literature and histopathological findings in nine patients. Eur Respir J 2000;15(2):373-381. https://doi.org/10.1034/ j.1399-3003.2000.15b25.x
SearlesG,McKendryRJ.Methotrexatepneumonitisin rheumatoid arthritis: Potential risk factors. Four case reports and a review of the literature. J Rheumatol 1987;14(6):1164-1171.
Barrera P, Laan RFJM, van Reil PLCM, Dekhuijen PNR, Boerbooms AMTh, van de Putte LBA. Methotrexate related pulmonary complications in rheumatoid arthritis. Ann Rheum Dis 1994;53(7):434- 439. https://doi.org/10.1136/ard.53.7.434
Gillespie AM, Lorigan PC, Radstone CR, Waterhouse JC, Coleman RE, Hancock BW. Pulmonary function in patients with trophoblastic disease treated with low-dose methotrexate. Br J Cancer 1997;76(10):1382- 1386. https://doi.org/10.1038/bjc.1997.564
Zhang D, Ding Z, Qian J, Xie X, Wang Y. Two rare cases of methotrexate-induced pneumonitis and pleurisy in patients with gestational trophoblastic neoplasms. Eur J Gynaecol Oncol 2008;29(4):390-392.